De persoon in kwestie, een 47-jarige gezonde man, overleed honderden dagen later onverwacht aan een longbloeding door een bloedprop die gelinkt is aan het Pfizer-vaccin.
De man bleek een vaccin te hebben gekregen uit één van de dodelijkste batches, schrijven onderzoekers Peter McCullough en Nicolas Hulscher. Het gaat om het eerste casusrapport over een dodelijke bijwerking die meer dan een jaar na mRNA-injectie optrad, stelt arts McCullough.
FDA wist ervan
Mensen kunnen dus meer dan een jaar na mRNA-vaccinatie nog sterven als gevolg van de bijwerkingen.
De Amerikaanse medicijnwaakhond FDA wist ervan, maar gaf toch groen licht om de vaccins uit te rollen.
(Video verwijderd? Klik hier...)
15 jaar
De FDA zei namelijk dat deze bloedproppen 5 tot 15 jaar later nog zouden kunnen ontstaan. Dat zeiden ze er niet bij toen ze iedereen adviseerden om zich te laten vaccineren.
Als mensen wisten dat een Pfizer-coronavaccin hen tot 15 jaar na injectie nog zou kunnen beschadigen of doden, zou iemand dan nog zo’n prik halen?
Meer hierover:
Over de auteur: Robin de Boer is economisch geograaf. Volg hem hier op Substack.
--------------------
BREAKING -
Peer-Reviewed Study Links COVID-19 mRNA 'Vaccination' to Fatal Pulmonary
Hemorrhage 555 Days Post-Injection
Our autopsy case
report is the first published instance of a fatal adverse event occurring more
than one year post-mRNA injection, highlighting the potential for serious
long-term adverse effects.
Feb 09, 2025
by Nicolas Hulscher, MPH
The McCullough Foundation study, authored by
epidemiologist Nicolas Hulscher and Dr. Peter McCullough, titled, Delayed
Fatal Pulmonary Hemorrhage Following Covid-19 Vaccination: Case Report, Batch
Analysis, And Proposed Autopsy Checklist, was just published after
successful peer-review in the International Journal of Innovative
Research in Medical Science:
Abstract
COVID-19 vaccines have been previously associated
with pulmonary hemorrhage, typically observed shortly after vaccination. We
present a healthy, 47-year-old Caucasian male that died unexpectedly from acute
pulmonary hemorrhage 555 days after completing the BNT162b2 (Pfizer) COVID-19
vaccination primary series. Before death, he exhibited symptoms of a
mild respiratory infection. Despite a healthy medical history and no medication
use, the patient’s condition rapidly deteriorated and he experienced severe
respiratory distress, followed by cardiopulmonary arrest with evidence of
profuse pulmonary bleeding. Autopsy
findings revealed massive lung congestion without embolism, normal heart size,
and moderate coronary atherosclerosis without myocardial infarction. Despite
these findings, the medical examiner determined the cause of death was
attributed to atherosclerotic and hypertensive cardiovascular disease, without
considering the recent pulmonary hemorrhage and unremarkable medical history.
The autopsy failed to investigate potential contributions from the COVID-19
vaccine, such as the presence of the Spike protein, vaccine mRNA, or related
antibodies. A batch analysis revealed the BNT162b2 vaccine batch this
patient received is among the top 2.8% for number of reported deaths out of all
Pfizer COVID-19 vaccine batches and is associated with fatal cardiovascular
adverse events including cardiac arrest. The evidence suggests that this man
died of a cardiopulmonary arrest most likely as a result of acute pulmonary
hemorrhage, with the COVID-19 vaccine potentially playing a role in the
development of cardiopulmonary pathology and hemorrhage. We propose
autopsy protocols for deceased individuals that have received one or more
COVID-19 vaccines to help improve diagnostic accuracy in future cases.
Our autopsy case report is the first published instance of a fatal adverse event occurring more than one year after a COVID-19 mRNA injection, highlighting the potential for serious long-term adverse effects. Healthcare providers are encouraged to be aware of and monitor for any long-term cardiopulmonary complications that may arise after COVID-19 ‘vaccination’.
This study also underscores the importance of
conducting COVID-19 ‘vaccine’ batch analyses when evaluating potential links
between adverse events and the injection:
Because the autopsy failed to investigate the
presence of COVID-19 vaccine-specific components, we conducted a thorough
analysis of the specific COVID-19 vaccine batch administered to this individual
using a digital resource known as "How Bad is My Batch?" [14]. This tool
aggregates data from VAERS [3], methodically organizing it to present all adverse events associated
with specific vaccine batches. This approach allows for a detailed and systematic
examination of the batch in question, providing a comprehensive view of any
potential adverse effects reported. The patient received two doses of a
BNT162b2 mRNA COVID-19 vaccine, which both belonged to the batch EW0175. A
review of batch information indicates there were 29 reports of death from his
batch through February 2, 2024, however, this case had not yet been reported to
VAERS. Batch EW0175 is among the top 2.8% for number of reported deaths out of
all Pfizer COVID-19 vaccine batches listed in VAERS (ranked 131 out of 4,730).
Analysis of batch EW0175 indicated the lethality of injection (number of deaths
among total EW0175 adverse event reports) was 1.69%. Among reported serious
adverse events in this batch, there were 14 respiratory failure, 11 thrombosis,
7 myocarditis, 6 pericarditis, 5 cardiac arrest, 5 myocardial infarction, and 4
pulmonary embolism reports (Figure 2).
Without proper post-mortem investigation into
specific COVID-19 vaccine components residing in blood and tissues, it is
difficult to confidently determine the cause of death in COVID-19 vaccinated
subjects that present anomalous symptoms, as in our case. To ensure a
comprehensive understanding of the potential impact of COVID-19 vaccines on
adverse fatal outcomes, it is critical to conduct specific tests during
postmortem procedures [15]. Thus, we propose an autopsy checklist for deceased individuals that have
received one or more COVID-19 vaccines to help improve diagnostic accuracy in
future cases (Table 1). The checklist indicates the vital need to test
for the presence of Spike protein and vaccine-derived mRNA within tissue
samples. Additionally, a detailed antibody profile should be established,
including tests for antibodies against platelet factor 4 (anti-PF-4), the
SARS-CoV-2 Spike protein, the nucleocapsid component of the virus, antinuclear
antibodies (ANA), and anti-neutrophil cytoplasmic antibodies (ANCA). Alongside
these tests, an assessment of inflammation specific to various organs is
necessary. These combined diagnostic efforts can reveal how the vaccine may
contribute to unexpected fatal events [15,16], especially since
most autopsies performed following COVID-19 vaccination don’t include
them [17]. This checklist is intended to complement existing
autopsy pathology standards by incorporating additional tests relevant to
suspected vaccine-related cases.
Primary pulmonary hemorrhage can occur after mRNA
COVID-19 vaccination [9-11]. The U.S. Food and Drug Administration Center for Biologics Evaluation
and Research (CBER) regulatory window of concern for a novel genetic product,
such as the BNT162b2 mRNA COVID-19 vaccine, is 5-15 years [22]. That means
unusual serious adverse events such as fatal pulmonary hemorrhage should not
only be reported to VAERS, but also be considered as being a consequence of the
novel product even months to years after the last injection. The COVID-19
vaccine batch EW0175 that this patient received has been associated with
cardiovascular, hematological, and respiratory adverse events and exhibits a
high degree of lethality compared to most batches. The Spike protein produced
from COVID-19 vaccine mRNA is known to cause bleeding, thrombosis and specific
hemorrhagic-thrombotic syndromes including vaccine-induced thrombotic
thrombocytopenia (VITT) which has been reported after the Pfizer vaccine [23-25]. The majority of
VITT cases arising from vaccine induced anti-platelet factor-4 antibodies
reported in the literature are caused by the adenoviral vector vaccines,
however, “long VITT” has been reported where findings last for months after
vaccine administration [26,27]. It is possible that any mild viral upper respiratory infection in a
mRNA COVID-19 vaccinated patient could result in acute hemorrhage. The systemic
circulation and extensive persistence (>4 months) of Spike protein from
COVID-19 vaccination likely accelerated asymptomatic coronary atherosclerosis,
pulmonary capillary disease, and alveolar inflammation as summarized by
Parry et al [15]. Furthermore, COVID-19 vaccine-modified mRNA has been shown to persist
in humans for up to 28 days [28]. The discovery of residual plasmid DNA, including spike-coding
sequences and the SV40 promoter/enhancer, in BNT162b2 vaccine lots highlights a
potential mechanism for genome integration, potentially enabling prolonged
spike protein production in transfected cells [29]. Incorporating our proposed autopsy checklist would
significantly improve diagnostic accuracy in this and similar cases reported
following COVID-19 vaccination [16,17].
Based on the totality of evidence, we conclude the
following:
In conclusion, this man died of a cardiopulmonary
arrest most likely as a result of acute pulmonary hemorrhage. The coronary
artery disease was coincident but was not the primary cause of the cardiac
arrest. Because the autopsy ruled out other possible causes of death and the
received BNT162b2 vaccine batch is associated with fatal hematological,
respiratory, and cardiovascular syndromes including cardiac arrest, prior
COVID-19 vaccination is potentially either the direct cause or contributed to
the causal pathway leading to death. COVID-19 vaccine-induced Spike protein may
have caused acceleration of asymptomatic coronary atherosclerosis via direct
vessel injury and inflammation. Our recommendation for a specialized autopsy
approach can help improve the diagnosis of COVID-19 vaccine-induced pathologies
in future cases. Healthcare providers are
encouraged to be aware of and monitor for any long-term cardiopulmonary
complications that may arise after COVID-19 vaccination.
Nicolas
Hulscher, MPH
Epidemiologist
and Foundation Administrator, McCullough Foundation
www.mcculloughfnd.org
Please
consider following both the McCullough Foundation and my personal account on X (formerly Twitter) for
further content.
Source :
https://www.thefocalpoints.com/p/breaking-peer-reviewed-study-links?r=14jb45
